Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-7680 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| GT1 Participants | EXPERIMENTAL | Participants take MK-7680 capsules by mouth once daily (QD) for 7 days. The starting dose will be 200 mg and the dose will be adjusted in successive panels of participants based on analysis of results of the previous panel. |
| GT3 Participants | EXPERIMENTAL | Participants take MK-7680 capsules by mouth QD for 7 days. The starting dose will be 200 mg and the dose will be adjusted in successive panels of participants based on analysis of results of the previous panel. |
| Name | Type | Description |
|---|---|---|
| MK-7680 | DRUG | MK-7680 10 mg and 100 mg capsules |
Inclusion Criteria: * Is in good health except for HCV infection * Is male or is a female of non-childbearing potential * Clinical diagnosis of HCV GT1 or GT3 with no evidence of mixed-GT or non-typeable infection Exclusion Criteria: * Has a history of clinically significant and not stably contro...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir |
| Abbott Laboratories | ABT | 2 | - | Undisclosed |
| AbbVie, Inc. | ABBV | 1 | - | Undisclosed |
MK-7680 is an investigational small molecule being developed for the treatment of Hepatitis C. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and is still being studied for safety and pharmacokinetics.
MK-7680 is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company is conducting clinical trials to evaluate the drug's safety and pharmacokinetics in participants with Hepatitis C.
MK-7680 is in Phase 1 clinical development. It is an investigational drug, not yet approved, and is being studied in a completed Phase 1 trial to assess its safety and pharmacokinetics in participants with Hepatitis C.
MK-7680 has been studied in one completed Phase 1 clinical trial, identified as NCT02269059. This trial, titled 'Safety and Pharmacokinetics of MK-7680 in Participants With Hepatitis C (MK-7680-003)', enrolled 13 participants with Hepatitis C.
MK-7680 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for Hepatitis C. The drug has completed a Phase 1 trial, but it has not yet received regulatory approval.